NCT02104804.

Trial name or title	Evaluate the efficacy and aafety of aaxagliptin added to insulin monotherapy or to insulin combined with metformin in Chinese subjects with type 2 diabetes who have inadequate glycaemic control
Methods	Double‐blind parallel‐group randomised controlled trial, phase 3 trial
Participants	Type 2 diabetes participants who have inadequate glycaemic control on insulin alone or on insulin in combination with metformin
Interventions	Saxagliptin (5 mg) + insulin vs placebo for saxagliptin + insulin
Outcomes	HbA1c, fasting glucose, insulin dose, (serious) adverse events (hypoglycaemia)
Starting date	2 April 2014
Contact information
Notes	AstraZeneca

HbA1c: glycosylated haemoglobin A1c